NasdaqGS - Nasdaq Real Time Price USD

Pliant Therapeutics, Inc. (PLRX)

1.6900

+0.0700

+(4.32%)

At close: May 2 at 4:00:00 PM EDT

1.7285

+0.04

+(2.28%)

After hours: May 2 at 7:47:25 PM EDT

Pliant cuts workforce by 45% following lung trial termination

Pliant is slashing 45% of its workforce in a move to “minimise costs and preserve cash reserves”.

Clinical Trials Arena yesterday

PLRX
+4.32%
Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

The FDA pushed back its decision date on Cytokinetics’ heart drug, while AstraZeneca got Phase 3 results that could help it expand use of a top drug.

BioPharma Dive yesterday

AZN

CYTK

PLRX
+4.32%
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activities for BEACON-IPF trial ongoing; topline data expected in the second quarter of 2025 SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a strategic restructuring of its workforce and other cost saving actions to extend the cash runway to su

GlobeNewswire 2 days ago

PLRX
+4.32%
PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know

PLIANT THERAPT (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 23 days ago

PLRX
+4.32%
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16-21, 2025. The following abstracts are posted on ATS 2025’s online itinerary planner for registered users. Pliant was selected for a featured oral presentation as part of the ATS 2025 Mini Sym

GlobeNewswire 26 days ago

PLRX
+4.32%
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know

Pliant stock crashes 89% in three months following setbacks in the mid-stage study of its lead candidate, bexotegrast, for idiopathic pulmonary fibrosis.

Zacks last month

PLRX
+4.32%
$Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination wi

GlobeNewswire last month

PLRX
+4.32%
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell and gene therapy pilot appeared to survive.

BioPharma Dive last month

SLRN

STRO

PLRX
+4.32%
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company’s common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to ga

GlobeNewswire last month

PLRX
+4.32%
Pliant Therapeutics stock tumbles amid IPF trial cancellation

The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

Clinical Trials Arena last month

PLRX
+4.32%

GLDAF
Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff after shelving two cell therapy programs.

BioPharma Dive last month

NMRA

SLRN

PLRX
+4.32%
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discont

GlobeNewswire last month

PLRX
+4.32%
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, Pliant has discontinued the BEACON-IPF Phase 2b trial evaluating bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). While an imbalance in unadjudicated IPF-relate

GlobeNewswire last month

PLRX
+4.32%
Blade Air Mobility Leads The Charge Among 3 US Penny Stocks

As the U.S. stock market flirts with record highs, investors are keenly watching for opportunities that may not be immediately apparent in the headlines. Penny stocks, often representing smaller or newer companies, continue to intrigue those looking beyond established giants for potential growth. Despite their historical reputation as speculative bets, some penny stocks today boast robust financial health and present intriguing possibilities for investors seeking unique opportunities.

Simply Wall St. 2 months ago

BLDE

BLDEW

NAUT
All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy

PLIANT THERAPT (PLRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 2 months ago

PLRX
+4.32%
Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump

Pliant Therapeutics' (PLRX) shares rose by than 32% in recent Thursday trading after the company sai

PREMIUM
MT Newswires 2 months ago

PLRX
+4.32%
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

BioPharma Dive 2 months ago

BIIB

ABBV

NMRA
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Pliant has initiated assembly of outside panel of world-renowned experts to review BEACON-IPF trial dataSOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that, per the charter of the trial’s independent Data Safety Monitoring Board (DSMB), the Company has initiated the assembly of an outside expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fib

GlobeNewswire 2 months ago

PLRX
+4.32%
Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan

JPMorgan downgraded Pliant Therapeutics (PLRX) to Neutral from Overweight without a price target after the company announced a voluntary pause to the enrollment, and dosing, of its Phase 2b BEACON trial based on the recommendation of the Data and Safety Monitoring Board. The news “portends a material fundamental setback for the program, either for reasons of safety or futile activity,” the analyst tells investors in a research note. The firm says that with little pipeline value beyond bexotogras

TipRanks 2 months ago

PLRX
+4.32%
Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive

The company halted enrollment and dosing for its BEACON-IPF Phase 2b trial based on a recommendation from the DSMB.

GuruFocus.com 2 months ago

PLRX
+4.32%

Performance Overview

Return	PLRX	S&P 500 (^GSPC)
YTD	-87.17%	-3.31%
1-Year	-87.25%	+12.29%
3-Year	-70.09%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pliant Therapeutics, Inc. (PLRX)

Pliant cuts workforce by 45% following lung trial termination

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Pliant Therapeutics stock tumbles amid IPF trial cancellation

Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Blade Air Mobility Leads The Charge Among 3 US Penny Stocks

All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy

Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan

Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive

Performance Overview